Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Class A Common Stock, $0.00001 par value per share
-
Shares outstanding
-
4,564,846
-
Total 13F shares
-
115,242
-
Share change
-
-254,018
-
Total reported value
-
$1,161,411
-
Price per share
-
$10.24
-
Number of holders
-
2
-
Value change
-
-$1,944,462
-
Number of sells
-
2
Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) as of Q4 2023
As of 31 Dec 2023,
RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) was held by
2 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
115,242 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, ARK Investment Management LLC, VANGUARD GROUP INC, Mubadala Investment Co PJSC, BlackRock Inc., STATE STREET CORP, FMR LLC, Kinnevik AB (publ), Nikko Asset Management Americas, Inc., and Sumitomo Mitsui Trust Holdings, Inc..
This page lists
194
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.